Navigation Links
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. today announced that Mr. Armando Anido, Chief Executive Officer and President, and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the 2007 CEUT Emerging Growth Opportunities Conference to be held July 10 through July 12, 2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido is scheduled to present an overview of the Company and its product pipeline at 4:30 PM Eastern Time on Wednesday, July 11, 2007.

To listen to the audio web cast of the presentation during or after the event, please visit: http://www.auxilium.com. The replay will be available for 90 days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase enzyme, is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in phase I of development. The Company is currently seeking a partner to further develop this product candidate. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to all indications using AA4500 for non-topical formulations. For additional info rmation, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 2007 CEUT Emerging Growth Opportunities Conference, and products in development for the treatment of Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward- looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's Annual Report on Form 10-Q for the quarter ended March 31, 2007 under the heading "Risk Factors", which is on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "Investor Relations -- SEC Filings." T here may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release.

CONTACT: James E. Fickenscher, Chief Financial Officer of AuxiliumPharmaceuticals, Inc., +1-484-321-5900, ; GregoryGin of Lazar Partners, Ltd., +1-212-867-1762, jfickenscher@auxilium.com ggin@lazarpartners.com

Web site: http://www.auxilium.com/

Ticker Symbol: (NASDAQ-NMS:AUXL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Babyscripts, Inc., the leading virtual ... technology company, has taken a minority position in the company by leading a ... , Babyscripts has spent the last four years building a clinically-validated, virtual care ...
(Date:1/7/2019)... ... ... uBiome, the leader in microbial genomics, announced today the release of a new ... support in metabolizing alcohol. , In the process of metabolizing alcohol, your microbiome ... your body. The new story provides an individualized abundance of two groups of gut ...
(Date:1/7/2019)... ... January 07, 2019 , ... Author Lisa Zschuschen ... calmed her. Meanwhile, photographer Patricia Ahearn discovered all the health benefits of forest ... granddaughter, Violet. Together, they invite readers to experience the power of nature through ...
Breaking Medicine Technology:
(Date:1/14/2019)... ... January 14, 2019 , ... Trees can be overweight too! ... have trees pruned, and winter is a great time to clean things up on ... lead to serious damage, especially during windy or icy storms. The crown of the ...
(Date:1/13/2019)... HARRISBURG, Pa. (PRWEB) , ... January 12, 2019 ... ... (PATS) Young Professionals Committee (YPC) in conjunction with Temple University hosted a continuing ... Between Mentors and Mentees. The event aimed to create a series of ...
(Date:1/11/2019)... ... January 11, 2019 , ... Ms. Barrios, a ... the U.S., alleges that Andrews and others engaged in a systematic pattern of ... referred to employees by race and by the color of their skin, and ...
(Date:1/10/2019)... ... January 10, 2019 , ... ... has partnered with MD101, a regulatory consulting company that serves the medical industry. ... in servicing companies in the medical device and healthcare industries. Based in France, ...
(Date:1/8/2019)... ... January 08, 2019 , ... Cigna-HealthSpring’s Medicare Advantage ... West End communities have a new option for their medical care with the ... , JenCare operates five centers in Atlanta that provide access to primary care ...
Breaking Medicine News(10 mins):